Tadalafil Tablet
Product Images NDC 70518-3864

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-3864). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Tadalafil 5 mg oral tablets, quantity 30, manufactured by RemedyRepack Inc. The label includes an NDC number 70518-3864-00, barcode, and a QR code. It contains warnings to keep out of reach of children and not to split tablets. Storage instructions and repackaging information are also visible.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework including fused rings and functional groups.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

Four line graphs depicting changes in blood pressure (BP) differences between tadalafil and placebo over time up to 96 hours. The charts show Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, with BP difference in mmHg on the y-axis and time in hours on the x-axis. Error bars indicate variability at each measured time point.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This figure shows two line graphs comparing systolic blood pressure changes over 24 hours post-dose. The top graph depicts standing systolic blood pressure (mmHg) and the bottom graph depicts supine systolic blood pressure (mmHg). Both graphs compare Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, plotted against time in hours.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, combined with doxazosin. The x-axis shows time after administration, and the y-axis shows systolic blood pressure changes. Four data series compare 20 mg tadalafil taken at 08:00 or 20:00 with placebo, each combined with 8 mg daily doxazosin.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). The graph compares three dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil after 5 consecutive days of administration. Concentration peaks and decreases are shown for each dosing pattern over a 120-hour period.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph depicting the change from baseline in IPSS total score over 12 weeks of treatment. It compares tadalafil tablets 5 mg with placebo, showing larger decreases in IPSS score for tadalafil over time with statistical significance indicated (p<0.01). The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS score.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph depicting change from baseline in IPSS Total Score over a 12-week treatment duration. It compares Tadalafil tablets 5 mg versus placebo, showing greater score reduction for Tadalafil. The graph includes data points at weeks 0, 1, 4, 8, and 12, with a statistical significance marker at p<0.01.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph depicting least squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline ranging from 0 to -7. Data points for both treatments are connected with lines, with statistical significance indicated at several points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. It compares Tadalafil tablets 5 mg and placebo, with data points at 0, 2, 4, 8, and 12 weeks. The graph indicates greater improvement with Tadalafil tablets compared to placebo, with statistical significance noted at week 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.